New PR as of today regarding the sales in Sweden since launch in February
Moberg Pharma AB's (OMX: MOB) reports strong interest from pharmacists, doctors and end customers in the launch of MOB-015 under the Terclara[®] brand in Sweden. A majority of Swedish pharmacies now have the product available on the shelf.
Interest in the product exceeds the chains' forecasts, and the pharmacy chains are increasing their orders due to the fact that Terclara® has occasionally sold out at several of the pharmacy chains. However, there is a well-stocked wholesale warehouse.
Great details on the potency. Any thoughts on Moberg’s plans resulting in equity dilution . I guess it’s a necessary evil for budding Pharma cos. Although In current their situation, I would have thought it’s not necessary .
Dilution is the main risk. Governance has historically been an issue (former CEO and founder drained the balance sheet thru a big dividend right before he quit for example). New CEO is old CFO, she doesn't own a ton of stock. OpEx is low though and if the product takes off in Europe we might never have to think about dilution again, regardless of management. Hard to be sure but those are my thoughts.
Cheers didn’t know about the governance problems ..I was curious to find what was causing the price to move negatively .
I guess you are aware of that in last year’s raise, participants were granted warrants whose exercise price is floating until this month. They’re being priced at the volume weighted average price from May 20th to the 31st.
Really good detail on the effectiveness of MOB-015. Welcome to the club.
New PR as of today regarding the sales in Sweden since launch in February
Moberg Pharma AB's (OMX: MOB) reports strong interest from pharmacists, doctors and end customers in the launch of MOB-015 under the Terclara[®] brand in Sweden. A majority of Swedish pharmacies now have the product available on the shelf.
Interest in the product exceeds the chains' forecasts, and the pharmacy chains are increasing their orders due to the fact that Terclara® has occasionally sold out at several of the pharmacy chains. However, there is a well-stocked wholesale warehouse.
https://www.mobergpharma.se/pressmeddelanden/2024-04-23/lanseringsuppdatering-mob-015
Welcome to the nail fungus street gang! Love the picture!
Thanks for the new piece and for getting into the details of the patent!
No problem, thanks for reading
Thanks Stephen,
Great details on the potency. Any thoughts on Moberg’s plans resulting in equity dilution . I guess it’s a necessary evil for budding Pharma cos. Although In current their situation, I would have thought it’s not necessary .
Dilution is the main risk. Governance has historically been an issue (former CEO and founder drained the balance sheet thru a big dividend right before he quit for example). New CEO is old CFO, she doesn't own a ton of stock. OpEx is low though and if the product takes off in Europe we might never have to think about dilution again, regardless of management. Hard to be sure but those are my thoughts.
Cheers didn’t know about the governance problems ..I was curious to find what was causing the price to move negatively .
I guess you are aware of that in last year’s raise, participants were granted warrants whose exercise price is floating until this month. They’re being priced at the volume weighted average price from May 20th to the 31st.
I take that will be a dilution .
Yes, up to 30%.
Did you mean Sweden listed Moberg . Ticker MOB. It dropped from 39 SEK on 7th May to 25 SEK on Friday.
It’s still 70% up YTD. I guess all depends on entry level .
Sorry, I meant that the dilution can be a max of 30% of the current shares outstanding, not the share price.